Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that leverages each company’s expertise in cell and gene therapies (CGTs).
Pharmalittle: We’re reading about a bill to force insurers to sell pharmacies, Lilly testing GLP-1 meds for addiction, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After
December 11, 2024